Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 08, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,150,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,402.34 pence per share.
- Treasury Holdings: 214,989,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,773,620,970 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 1,150,000 shares on November 08, 2006, increasing its Treasury stock position. No other material changes to operations or financial condition are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 1,150,000 shares by 1,402.34 pence.
- Confirm the updated total share capital structure (5,773,620,970 issued shares plus 214,989,678 Treasury shares).
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and capital allocation strategy.